Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $10.1 million.

  • Compass Therapeutics' Non-Current Assets rose 2656.35% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year increase of 12819.05%. This contributed to the annual value of $7.7 million for FY2024, which is 15557.78% up from last year.
  • Per Compass Therapeutics' latest filing, its Non-Current Assets stood at $10.1 million for Q3 2025, which was up 2656.35% from $10.5 million recorded in Q2 2025.
  • Compass Therapeutics' Non-Current Assets' 5-year high stood at $10.5 million during Q2 2025, with a 5-year trough of $2.1 million in Q2 2024.
  • For the 3-year period, Compass Therapeutics' Non-Current Assets averaged around $5.7 million, with its median value being $4.4 million (2023).
  • Its Non-Current Assets has fluctuated over the past 5 years, first plummeted by 4717.32% in 2024, then skyrocketed by 40861.99% in 2025.
  • Quarter analysis of 3 years shows Compass Therapeutics' Non-Current Assets stood at $3.0 million in 2023, then skyrocketed by 155.58% to $7.7 million in 2024, then surged by 32.5% to $10.1 million in 2025.
  • Its Non-Current Assets was $10.1 million in Q3 2025, compared to $10.5 million in Q2 2025 and $7.3 million in Q1 2025.